Robert Hettle

824 total citations
63 papers, 547 citations indexed

About

Robert Hettle is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Economics and Econometrics. According to data from OpenAlex, Robert Hettle has authored 63 papers receiving a total of 547 indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Oncology, 21 papers in Pulmonary and Respiratory Medicine and 21 papers in Economics and Econometrics. Recurrent topics in Robert Hettle's work include PARP inhibition in cancer therapy (25 papers), Health Systems, Economic Evaluations, Quality of Life (15 papers) and Advanced Breast Cancer Therapies (14 papers). Robert Hettle is often cited by papers focused on PARP inhibition in cancer therapy (25 papers), Health Systems, Economic Evaluations, Quality of Life (15 papers) and Advanced Breast Cancer Therapies (14 papers). Robert Hettle collaborates with scholars based in United Kingdom, United States and Italy. Robert Hettle's co-authors include Nerys Woolacott, Stephen Palmer, Mark Corbett, Sebastian Hinde, Julie Jones-Diette, Robert Hodgson, Mohd Kashif Siddiqui, Ishant Khurana, Lara J. Wolfson and Anna N. Walker and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and PLoS ONE.

In The Last Decade

Robert Hettle

62 papers receiving 541 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Robert Hettle United Kingdom	11	265	117	116	95	78	63	547
Giovanni Tazzioli Italy	11	208 0.8×	55 0.5×	30 0.3×	85 0.9×	77 1.0×	43	489
John Broggio United Kingdom	15	373 1.4×	83 0.7×	45 0.4×	102 1.1×	71 0.9×	33	672
Ghulam Rehman Mohyuddin United States	13	317 1.2×	39 0.3×	59 0.5×	41 0.4×	35 0.4×	129	629
Serafina Mammoliti Italy	17	439 1.7×	113 1.0×	22 0.2×	143 1.5×	42 0.5×	50	841
Kelsey L. Corrigan United States	12	296 1.1×	54 0.5×	52 0.4×	97 1.0×	22 0.3×	52	585
Abdellatif Benider Morocco	16	498 1.9×	119 1.0×	28 0.2×	106 1.1×	50 0.6×	102	906
Rachel Abudu United Kingdom	4	198 0.7×	41 0.4×	59 0.5×	64 0.7×	26 0.3×	7	393
Benjamin J. Resio United States	13	281 1.1×	35 0.3×	66 0.6×	157 1.7×	104 1.3×	32	980
Sérgio D. Simon Brazil	14	506 1.9×	32 0.3×	53 0.5×	173 1.8×	75 1.0×	46	773
Vinícius F. Calsavara Brazil	14	319 1.2×	52 0.4×	18 0.2×	167 1.8×	19 0.2×	89	760

Countries citing papers authored by Robert Hettle

Since Specialization

Citations

This map shows the geographic impact of Robert Hettle's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Robert Hettle with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Robert Hettle more than expected).

Fields of papers citing papers by Robert Hettle

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Robert Hettle. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Robert Hettle. The network helps show where Robert Hettle may publish in the future.

Co-authorship network of co-authors of Robert Hettle

This figure shows the co-authorship network connecting the top 25 collaborators of Robert Hettle. A scholar is included among the top collaborators of Robert Hettle based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Robert Hettle. Robert Hettle is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Ekman, Mattias, et al.. (2023). Cost-Effectiveness Analysis of Adjuvant Olaparib Versus Watch and Wait in the Treatment of Germline BRCA1/2-Mutated, High-Risk, HER2-Negative Early Breast Cancer in Sweden. PharmacoEconomics - Open. 8(2). 277–289. 2 indexed citations

Ghia, Paolo, Alan P Skarbnik, Michele Miranda, et al.. (2023). A MATCHING‐ADJUSTED INDIRECT COMPARISON OF THE EFFICACY AND SAFETY OF ACALABRUTINIB VERSUS ZANUBRUTINIB IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA. Hematological Oncology. 41(S2). 742–743. 1 indexed citations

Kindler, Hedy L., et al.. (2023). Patient‐centered outcomes in the POLO study of active maintenance olaparib for germline BRCA‐mutated metastatic pancreatic cancer. Cancer. 129(9). 1411–1418. 8 indexed citations

Skarbnik, Alan P, Adam S. Kittai, Jack Roos, et al.. (2023). P642: A MATCHING-ADJUSTED INDIRECT COMPARISON OF THE EFFICACY AND SAFETY OF ACALABRUTINIB VERSUS ZANUBRUTINIB IN RELAPSED OR REFRACTORY CHRONIC LYMPHOCYTIC LEUKEMIA. HemaSphere. 7(S3). e4236347–e4236347. 2 indexed citations

Tan, David S.P., et al.. (2021). Cost-effectiveness of olaparib versus routine surveillance in the maintenance setting for patients withBRCA-mutated advanced ovarian cancer after response to first-line platinum-based chemotherapy in Singapore. Journal of Gynecologic Oncology. 32(2). e27–e27. 6 indexed citations

Evans, Rachel, Neil Hawkins, Dominic Muston, et al.. (2021). Exploring the Impact of Treatment Switching on Overall Survival from the PROfound Study in Homologous Recombination Repair (HRR)-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC). Targeted Oncology. 16(5). 613–623. 5 indexed citations

Faivre‐Finn, Corinne, David H. Jackson, Keith R. Abrams, et al.. (2021). 84P Predicting longer-term progression-free survival (PFS) with durvalumab after chemoradiotherapy (CRT) in unresectable stage III NSCLC using a mixture cure model (MCM). Annals of Oncology. 32. S1408–S1409. 1 indexed citations

Agarwal, Neeraj, Keith R. Abrams, Dominic Muston, et al.. (2020). 622P Exploring the impact of treatment switching on the interim overall survival (OS) results of the PROfound study. Annals of Oncology. 31. S514–S514. 1 indexed citations

Robson, Mark E., Kathryn J. Ruddy, Seock‐Ah Im, et al.. (2019). Patient-reported outcomes in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer receiving olaparib versus chemotherapy in the OlympiAD trial. European Journal of Cancer. 120. 20–30. 57 indexed citations

10.

Latimer, Nicholas, et al.. (2019). Assessing the Long-Term Effectiveness of Cladribine vs. Placebo in the Relapsing-Remitting Multiple Sclerosis CLARITY Randomized Controlled Trial and CLARITY Extension Using Treatment Switching Adjustment Methods. Advances in Therapy. 37(1). 225–239. 1 indexed citations

11.

Macdonald, David W., et al.. (2019). PCN207 COST COMPARISON OF ADVERSE EVENT MANAGEMENT WITH POLY(ADP-RIBOSE) POLYMERASE (PARP) INHIBITORS OR CHEMOTHERAPY IN GBRCA-MUTATED, HER2-NEGATIVE ADVANCED BREAST CANCER (ABC): A US AND GERMAN HEALTHCARE PERSPECTIVE. Value in Health. 22. S476–S476. 2 indexed citations

12.

Hettle, Robert, et al.. (2018). Cost-effectiveness of cladribine tablets, alemtuzumab, and natalizumab in the treatment of relapsing-remitting multiple sclerosis with high disease activity in England. Journal of Medical Economics. 21(7). 676–686. 30 indexed citations

13.

Aldridge, Julie, et al.. (2018). Analysis of 6-month Confirmed Disability Progression in RRMS Patients Treated with Subcutaneous Interferon beta-1a (P6.361). Neurology. 90(15_supplement). 1 indexed citations

14.

Robson, Mark E., et al.. (2018). Estimating the Health State Utility of Patients with HER2– gBRCA+ Metastatic Breast Cancer Treated with Olaparib or Chemotherapy Via A Mapping Analysis of Eortc QLQ-C30 Data Collected in the Olympiad Clinical Trial. Value in Health. 21. S12–S12. 1 indexed citations

15.

Latimer, Nicholas, et al.. (2017). Impact Of Non-Randomised Drop-Out On Treatment Switching Adjustment In The Relapsing-Remitting Multiple Sclerosis Clarity Trial And The Clarity Extension Study. Value in Health. 20(9). A769–A769. 1 indexed citations

16.

Suri, Gaurav, Rohit Mistry, Robert Hettle, et al.. (2017). Cost Effectiveness of Ribociclib Plus Letrozole Versus Palbociclib Plus Letrozole for The Treatment of Post-Menopausal Women with Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2-Negative (HER2-) Advanced or Metastatic Breast Cancer from A US Private Third-Party Payer Perspective. Value in Health. 20(9). A436–A436. 1 indexed citations

17.

Mistry, Rohit, Gaurav Suri, Robert Hettle, et al.. (2017). Budget Impact of Ribociclib Plus Letrozole For The Treatment of Post-Menopausal Women With Hormone Receptor-Positive (HR+), Human Epidermal Growth Factor Receptor 2- Negative (HER2-) Advanced or Metastatic Breast Cancer From A US Private Third-Party Payer Perspective. Value in Health. 20(9). A422–A423. 1 indexed citations

18.

Hettle, Robert, et al.. (2017). Comparative Efficacy And Safety of Olaparib 400 Mg Capsules Bid And Niraparib 300 Mg Tablets QD As Maintenance Treatment After Response To Chemotherapy In Patients with Platinum-Sensitive Relapsed Non-Germline BRCA-Mutated Ovarian Cancer (PSROC). Value in Health. 20(9). A412–A412. 1 indexed citations

19.

Wolfson, Lara J., et al.. (2015). Cost-Effectiveness of Adding Bedaquiline to Drug Regimens for the Treatment of Multidrug-Resistant Tuberculosis in the UK. PLoS ONE. 10(3). e0120763–e0120763. 38 indexed citations

20.

Wolfson, Lara J., et al.. (2014). Cost Effectiveness of Bedaquiline for the Treatment of Multidrug-Resistant Tuberculosis. Value in Health. 17(7). A595–A595. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact